When you fill a prescription and see the price tag, you're looking at a number that may have little connection to what anyone actually pays. Behind that sticker price sits a layered system of negotiations, kickbacks, and intermediaries that few patients—and even few physicians—fully understand.

At the heart of this system are drug rebates: payments that pharmaceutical manufacturers make to middlemen called pharmacy benefit managers, or PBMs. In theory, these rebates reduce costs. In practice, they've created a set of incentives so warped that they may be raising the price of medicine for the people who need it most.

Understanding how rebates flow—and where the money actually lands—is essential for anyone trying to make sense of why American drug prices behave so differently from prices in almost every other market. The mechanics aren't intuitive, but they explain a great deal.

Here's the basic architecture. A drug manufacturer sets a list price—sometimes called the wholesale acquisition cost—for a medication. That's the headline number. But in practice, the manufacturer negotiates confidential rebates with pharmacy benefit managers, the companies that manage prescription drug coverage for insurers and employers.

PBMs decide which drugs appear on formularies—the lists of medications a health plan will cover and at what cost-sharing tier. Manufacturers compete for favorable placement by offering larger rebates. A brand-name cholesterol drug, for example, might offer a 40% rebate to land on a preferred tier, while a competitor offers 25%. The PBM selects the higher bidder, and the rebate flows back after the sale.

Where does that money go? This is where transparency breaks down. PBMs may pass some portion of the rebate to the insurer or employer, which can theoretically lower premiums. But PBMs also retain a share—sometimes a substantial one—as revenue. The patient at the pharmacy counter, meanwhile, often pays a copay or coinsurance calculated on the pre-rebate list price, not the net price after discounts.

The result is a system where the people paying the highest out-of-pocket costs are frequently those least shielded by insurance—patients in high-deductible plans, the uninsured, or those on coinsurance structures. The rebate creates savings somewhere in the supply chain, but that somewhere is often far from the patient.

Takeaway

Rebates don't reduce drug costs so much as reroute them. The discount exists, but it often flows to intermediaries rather than to the person handing over money at the pharmacy counter.

The rebate system creates a genuinely perverse incentive: manufacturers are rewarded for raising their list prices. Here's why. If a PBM negotiates rebates as a percentage of the list price, a higher list price means a larger absolute rebate in dollars. A 30% rebate on a $100 drug is $30. On a $500 drug, it's $150. The PBM looks more effective. The manufacturer secures formulary placement. Both parties benefit from the inflated number.

This dynamic helps explain a pattern that has baffled observers for years: drug list prices in the United States rise steadily, often well above inflation, even when competition exists. Between 2007 and 2018, list prices for brand-name drugs roughly doubled on average, while net prices—after rebates—grew far more modestly. The gap between list and net has widened into a chasm.

But that chasm isn't harmless. List prices anchor what the uninsured pay. They anchor coinsurance calculations. They anchor the catastrophic coverage thresholds in Medicare Part D, affecting when the government picks up costs. Every stakeholder downstream of the list price absorbs distortion, even if the negotiated net price tells a different story.

Victor Fuchs, the health economist, long argued that understanding healthcare costs requires following incentives rather than intentions. The rebate system is a textbook case. No single actor set out to inflate prices. But the structural incentives of percentage-based rebates, confidential negotiations, and misaligned cost-sharing created an escalator that is remarkably difficult to step off.

Takeaway

When intermediaries profit from higher sticker prices, the system doesn't optimize for affordability—it optimizes for the size of the discount itself, which is a fundamentally different goal.

The most prominent reform idea is deceptively simple: require that rebates be passed through to patients at the point of sale. Instead of paying coinsurance on a $500 list price, the patient would pay based on the $350 net price. The Trump and Biden administrations both explored versions of this policy, particularly within Medicare Part D.

Point-of-sale rebates would deliver immediate, visible relief to patients with high cost-sharing—especially those taking expensive brand-name medications for chronic conditions. Modeling by the Congressional Budget Office and others suggests meaningful reductions in out-of-pocket spending for the sickest beneficiaries. For the person choosing between filling a prescription and paying rent, this matters enormously.

But the policy has trade-offs that are easy to overlook. If rebates flow to patients instead of insurers, premiums may rise to compensate. The savings are redistributed, not created from thin air. Healthier enrollees who rarely fill expensive prescriptions could see higher monthly costs, while sicker enrollees benefit. Whether that redistribution is desirable is ultimately a values question, not just an economic one.

Other proposals go further: banning spread pricing (where PBMs charge plans more than they pay pharmacies and pocket the difference), requiring rebate transparency, or delinking PBM compensation from list prices entirely. Each approach targets a different node in the system. No single reform addresses every distortion, because the distortions are layered and interdependent. Meaningful change likely requires attacking the problem from multiple angles simultaneously.

Takeaway

Point-of-sale rebates help the sickest patients but shift costs to premiums. Evaluating any reform requires asking not just whether it reduces spending, but for whom—and at whose expense.

The drug rebate system is not a conspiracy. It's an emergent structure—built from rational decisions by manufacturers, PBMs, and insurers—that produces irrational outcomes for patients. Understanding it requires moving past villains and toward mechanics.

Reform is possible, but it demands honest reckoning with trade-offs. Redirecting rebates to patients helps the vulnerable but raises costs elsewhere. Transparency requirements change behavior but don't eliminate underlying incentives. Structural change means redesigning how intermediaries are compensated, not just how discounts are distributed.

The price on your prescription label is the final artifact of a negotiation you were never part of. That's worth understanding—and worth questioning.